Massive study reveals hidden cancer risk in rare gut tumor patients
NCT ID NCT07291752
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study analyzed data from over 93,000 people diagnosed with a gastrointestinal carcinoid tumor between 2000 and 2022. Researchers wanted to find out if these patients are more likely to develop a second, different gastrointestinal cancer. They used a large cancer database to calculate the risk. The study did not involve any new treatments or interventions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Two-Drug combo aims to stall rare gut tumors
- New CT technique may spot Hard-to-Find gut tumors
- New hope for rare tumors: tarlatamab trial opens
- Could a simple dose change make a tough cancer drug easier to take?
- 93,000 patients studied: what decades of data reveal about carcinoid cancer survival
- Big data reveals shifting patterns in rare cancer diagnosis